Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Resection, IP Chemo, and Radiation for Peritoneal Mesothelioma
NCT00024271Phase 2Unknown
- Sponsor
- Herbert Irving Comprehensive Cancer Center
- Start
- May 2001
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, doxorubicin, gemcitabine, interferon gamma-1b and mitomycin c in peritoneal mesothelioma, sponsored by Herbert Irving Comprehensive Cancer Center. Primary endpoint: Response Rate. Status: unknown.
02
Drugs
cisplatindoxorubicingemcitabineinterferon gamma-1bmitomycin c
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on NCT00024271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024271.